创新药行情的热度,堪比近期的高温天气,一路“狂飙”。5月20日,三生制药宣布,公司及附属子公司与辉瑞签署协议,将向辉瑞独家授予公司自主研发的突破性PD-1/VEGF双特异性抗体SSGJ-707在全球(不包括中国内地)的开发、生产、商业化权利,同时保留中国内地的权益。此次授权协议总额高达60.5亿美元。6月3日,百利天恒举办交流会解读2025年美国临床肿瘤学会(ASCO)年会数据,吸引130多家机构...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.